Frontlight ResearchEarly access
WithdrawnPhase 3
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH
Key facts
- Who runs it
- Sagimet Biosciences Inc.
- Trial code
- Status
- Withdrawn
- Phase
- Phase 3
- Started
- Mar 2025
- Expected to end
- Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- denifanstat
- Placebo
- Record updated
- 15 May 2025
- Why it stopped
- Business decision
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 43 criteriaShow less
Who can take part
- Willing and able to participate in the study and provide written informed consent
- Adults between 18 and 75 years of age
- Body mass index (BMI) ≥23 kg/m2 for Asian patients and ≥25 kg/m2 for patients of other races
- Presence of metabolic risk factor(s), as follows:
- T2DM; OR
- At least 2 out of 4 of the following:; BMI ≥30 kg/m2,; Hypertension, or on active antihypertensive treatment; Elevated fasting serum TGs or on active treatment for hypertriglyceridemia; Reduced fasting serum HDL-c, or on active treatment for dyslipidemia
- For patients with T2DM:
- HbA1c ≤9.5%
- If treatment naive: patients must have been diagnosed for at least 12 weeks prior to screening
- Suspected or confirmed diagnosis of MASH or MASLD or non-invasively diagnosed MASH or MASLD
- Stable ALT and AST levels
Who cannot take part
- Previous intake of an approved MASH medication
- History of excessive alcohol intake for a period of more than 3 consecutive months within 1 year prior to screening
- Prior or planned bariatric surgery
- Gain or loss of >5% of body weight in the 3 months or >10% of body weight in the 6 months prior to screening, qualifying liver biopsy, and the baseline visit (V1)
- Any of the following conditions or procedures within 6 months prior to the baseline visit (V1):
- Malignancy with a complete remission date within 5 years prior to the baseline visit (V1)
- Use of a nonpermitted concomitant medication within 30 days or 5 half-lives prior to screening
- Presence of cirrhosis on liver histology and/or cross-sectional imaging evidence consistent with cirrhosis and/or portal hypertension
- Evidence of another form of active liver disease
- Positive serologic evidence of current infectious liver disease
- Planned or history of liver transplantation
- Myocardial infarction
- Cardiac revascularization surgery
- Unstable angina
- Transient ischemic attack, stroke, or cerebrovascular disease
- Unstable or undiagnosed arrhythmias
- Any current or history of hepatocellular carcinoma
- Diabetes other than T2DM
- Any other known serious disease or other disease which in the Investigator's opinion would exclude the patient from participating in the study
- Exclusionary laboratory values:
- ALT and/or AST >5 × ULN
- ALP ≥2 × ULN
- Total serum bilirubin concentration >1.3 mg/dL
- Serum albumin concentration <3.5 g/dL
- International normalized ratio (INR) >1.3, except for patients receiving anticoagulant treatment
- Platelet count <140,000/μL
- Fasting TG level ≥500 mg/dL
- eGFR <45 mL/min/1.73 m2
- Current or historical clinically evident hepatic decompensation
- MELD score ≥12
- Uncontrolled high BP
- Uncontrolled hypothyroidism
About the trial
What the trial wants to find out
A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of denifanstat 50 mg compared to placebo in patients with metabolic dysfunction-associated steatotic liver disease (MALSD)/metabolic dysfunction-associated steatohepatitis (MASH) after 52 weeks of treatment.
The 2 groups in the trial
- Denifanstat 50 mgTreatment being tested
Denifanstat tablet, orally, once daily
Treatment: denifanstat
- PlaceboPlacebo, for comparison
Placebo tablet, orally, once daily
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Denifanstat in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MALSD)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Record updated
- 15 May 2025